«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 07

Page:

1272-1277

Research Field:

Publishing date:

Info

Title:

Clinical significance of PD-L1 expression and CD8+TILs in non-terminal respiratory unit adenocarcinoma of the lung

Author(s):

JI Yuexia¹; YANG Yang²; ZHANG Hanjie¹; TAO Jingxia¹; GUO Tianwei¹; LIU Qian²; LIU Biao²

1.Department of Pathology,Changshu Hospital Affiliated to Nanjing University of Traditional Chinese Medicine,Jiangsu Changshu 215516,China;2.Department of Pathology,Suzhou Hospital Affiliated to Nanjing Medical University,Jiangsu Suzhou 215006,China.

Keywords:

lung adenocarcinoma; non-terminal respiratory unit; PD-L1; CD8; TILs

PACS:

R734.2

DOI:

10.3969/j.issn.1672-4992.2024.07.015

Abstract:

Objective:To explore the clinical significance of PD-L1 expression and CD8+tumor infiltrating lymphocytes(TILs) in non-terminal respiratory unit adenocarcinomas(non-TRU ADCs) of the lung.Methods:The clinicopathological data of 85 cases of pulmonary non-TRU ADCs(stage I-IV) which underwent complete resection were retrospectively studied.Immunohistochemical methods were used to detect the expression of PD-L1,p53,and four mismatch repair proteins(MLH1,MSH2,MSH6,and PMS2),as well as CD8+TILs level.EGFR,KRAS gene mutations and ALK fusion gene were tested by the ARMS-PCR and FISH.The follow-up data were conducted to analyze the patients' prognosis.Results:Among 85 cases of non-TRU ADC,PD-L1 was negative in 34(40.0%) cases,low expression in 36(42.4%) cases and high expression in 15(17.6%) cases.PD-L1 expression was more common in patients with tobacco smoking(P＜0.05),invasive non-mucinous ADCs(P＜0.01),higher grade(P＜0.05),visceral pleural infiltration(P＜0.05) and KRAS mutations(P＜0.05).There were 17 cases of low level CD8+TILs(20.0%),42 cases of medium level CD8+TILs(49.4%) and 26 cases of high level CD8+TILs(30.6%).Medium-high level CD8+TILs were more common in patients with younger age (P＜0.05),tobacco smoking(P＜0.01),smaller tumor size(P＜0.05),invasive non-mucinous ADCs(P＜0.01),higher grade(P＜0.01) and p53 abnormal expression(P＜0.01).No significant correlation was showed between PD-L1 expression and CD8+TILs level by evaluating with Spearman rank correlation analysis(P＞0.05).The overall survival(OS) of patients with high level CD8+TILs was significantly higher than that of patients with low-medium level CD8+TILs(P＜0.05).No statistically signifificant differences,in terms of OS and disease-free survival(DFS),were observed in different PD-L1 expression subgroups,as well as DFS in different levels of CD8+TILs(P＞0.05,respectively).Conclusion:Non-TRU ADCs often express PD-L1 and have a high density of CD8+TILs,indicating that patients might benefit from ICIs treatment.High density CD8+TILs could serve as an auxiliary prognostic indicator for non-TRU ADC patients.

References:

[1] NICHOLSON AG,TSAO MS,BEASLEY MB,et al.The 2021 WHO classification of lung tumors:impact of advances since 2015［J］.J Thorac Oncol,2022,17(3):362-387.
[2] OKUDELA K,ARAI H,KITAMURA H,et al.A subpopulation of airway epithelial cells that express hepatocyte nuclear factor 4α - its implication in the development of non-terminal respiratory unit-type lung adenocarcinoma［J］.Histol Histopathol,2019,34(11):1217-1227.
[3] KOH MJ,SHIN DH,LEE SJ,et al.Gastric-type gene expression and phenotype in non-terminal respiratory unit type adenocarcinoma of the lung with invasive mucinous adenocarcinoma morphology［J］.Histopathology,2020,76(6):898-905.
[4] 刘标,吴楠,沈勤,等.肺非终末呼吸单元型腺癌的临床病理学观察［J］.中华病理学杂志,2018,47(8):603-608. LIU B,WU N,SHEN Q,et al.Lung non-terminal respiratory unit type adenocarcinoma:a clinicopathologic study［J］.Chinese Journal of Pathology,2018,47(8):603-608.
[5] Who Classification of Tumours Editorial Board.WHO classification of tumours-thoracic tumours［M］.5th ed.Lyon:International Agency for Research on Cancer,2021:64-74.
[6] GOW CH,HSIEH MS,LIU YN,et al.Clinicopathological features and survival outcomes of primary pulmonary invasive mucinous adenocarcinoma［J］.Cancers,2021,13(16):4103.
[7] VERMIJ L,LEON-CASTILLO A,SINGH N,et al.P53 immunohistochemistry in endometrial cancer:clinical and molecular correlates in the PORTEC-3 trial［J］.Mod Pathol,2022,35(10):1475-1483.
[8] GARASSINO MC,GADGEEL S,SPERANZA G,et al.Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer:5-year outcomes from the phase 3 KEYNOTE-189 study［J］.J Clin Oncol,2023,41(11):1992-1998.
[9] DE CASTRO G JR,KUDABA I,WU YL,et al.Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥1% in the KEYNOTE-042 study［J］.J Clin Oncol,2023,41(11):1986-1991.
[10] MIYAZAWA T,MARUSHIMA H,SAJI H,et al.PD-L1 expression in non-small-cell lung cancer including various adenocarcinoma subtypes［J］.Ann Thorac Cardiovasc Surg,2019,25(1):1-9.
[11] CRUZ-RICO G,AVILES-SALAS A,POPA-NAVARRO X,et al.Association of lung adenocarcinoma subtypes according to the IASLC/ATS/ERS classification and programmed cell death ligand 1(PD-L1) expression in tumor cells［J］.Pathol Oncol Res,2021,27:597499.
[12] ZHANG ML,KEM M,MOORADIAN MJ,et al.Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas［J］.Mod Pathol,2019,32(4):511-523.
[13] TAKADA K,TOYOKAWA G,KINOSHITA F,et al.Expression of PD-L1,PD-L2,and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype［J］.J Cancer Res Clin Oncol,2020,146(10):2639-2650.
[14] XU X,LI N,WANG D,et al.Clinical relevance of PD-L1 expression and CD8+ T cells' infiltration in patients with lung invasive mucinous adenocarcinoma［J］.Front Oncol,2021,11:683432.
[15] ZHANG M,LI G,WANG Y,et al.PD-L1 expression in lung cancer and its correlation with driver mutations:a meta-analysis［J］.Sci Rep,2017,7:10255.
[16] SONG P,GUO L,LI W,et al.Clinicopathologic correlation with expression of PD-L1 on both tumor cells and tumor-infiltrating immune cells in patients with non-small cell lung cancer［J］.J Immunother,2019,42(1):23-28.
[17] SCHOENFELD AJ,RIZVI H,BANDLAMUDI C,et al.Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas［J］.Ann Oncol,2020,31(5):599-608.
[18] HILTBRUNNER S,CORDS L,KASSER S,et al.Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype［J］.Nat Commun,2023,14(1):5154.
[19] MICHELE W L TENG,SHIN FOONG NGIOW,ANTONI RIBAS,et al.Classifying cancers based on T-cell infltration and PD-L1［J］.Cancer Res,2015,75(11):2139-2145.
[20] CUI S,DONG L,QIAN J,et al.Classifying non-small cell lung cancer by status of programmed cell death ligand 1 and tumor-infiltrating lymphocytes on tumor cells［J］.J Cancer,2018,9(1):129-134.
[21] KOH J,GO H,KEAM B,et al.Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma:comparison with histology and driver oncogenic alteration status［J］.Mod Pathol,2015,28(9):1154-1166.
[22] BRODY R,ZHANG Y,BALLAS M,et al.PD-L1 expression in advanced NSCLC:insights into risk stratifcation and treatment selection from a systematic literature review［J］.Lung Cancer,2017,112:200-215.
[23] GARG G,PRASAD KT,SINGH N,et al.Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer:association with clinicopathologic parameters［J］.J Pathol Transl Med,2021,55(6):398-405.
[24] BIE F,TIAN H,SUN N,et al.Comprehensive analysis of PD-L1expression,tumor-infiltrating lymphocytes,and tumor microenvironment in LUAD:differences between Asians and Caucasians［J］.Clin Epigenetics,2021,13(1):229.

Memo

Memo:

江苏省苏州市姑苏卫生人才计划人才科研项目(编号：GSWS2021037)；江苏省常熟市科技发展计划(社会发展)项目(编号：CS202228)

Common functions

Last Update: 2024-02-29